List of Tables
Summary Table: Global Market for Protein Drugs, by Region, Through 2029
Table 1: Evolution of Therapeutic Proteins, 1950s to Present
Table 2: Global Cancer Incidence and Mortality Cases, by WHO Region, 2022
Table 3: Therapeutic Area Distribution of Approved Antibody Drugs, 2023*
Table 4: Global Market for Protein Drugs, by Type, Through 2029
Table 5: Global Market for MAbs, by Type, Through 2029
Table 6: Global Market for MAbs, by Region, Through 2029
Table 7: Global Market for Human MAbs, by Region, Through 2029
Table 8: Global Market for Humanized MAbs, by Region, Through 2029
Table 9: Global Market for Chimeric MAbs, by Region, Through 2029
Table 10: Global Market for Murine MAbs, by Region, Through 2029
Table 11: Global Market for Peptide Hormones, by Type, Through 2029
Table 12: Global Market for Peptide Hormones, by Region, Through 2029
Table 13: Global Market for Insulin, by Region, Through 2029Global Market for Insulin, by Region, Through 2029
Table 14: Global Market for EPO, by Region, Through 2029
Table 15: Global Market for Growth Hormones, by Region, Through 2029
Table 16: Global Market for Other Peptide Hormones, by Region, Through 2029
Table 17: Global Market for Protein Vaccines, by Type, Through 2029
Table 18: Global Market for Protein Vaccines, by Region, Through 2029
Table 19: Global Market for Bacterial Vaccines, by Region, Through 2029
Table 20: Global Market for Viral Vaccines, by Region, Through 2029
Table 21: Global Market for Other Protein Vaccines, by Region, Through 2029
Table 22: Global Market for Blood Factors, by Type, Through 2029
Table 23: Global Market for Blood Factors, by Region, Through 2029
Table 24: Global Market for Coagulation Factors, by Region, Through 2029
Table 25: Global Market for Immunoglobulins, by Region, Through 2029
Table 26: Global Market for Other Blood Factors, by Region, Through 2029
Table 27: Global Market for Cytokines, by Type, Through 2029
Table 28: Global Market for Cytokines, by Region, Through 2029
Table 29: Global Market for Interleukins, by Region, Through 2029
Table 30: Global Market for Interferons, by Region, Through 2029
Table 31: Global Market for G-CSF, by Region, Through 2029
Table 32: Global Market for Therapeutic Enzymes, by Type, Through 2029
Table 33: Global Market for Therapeutic Enzymes, by Region, Through 2029
Table 34: Global Market for Lysosomal Enzymes, by Region, Through 2029
Table 35: Global Market for Thrombolytic Enzymes, by Region, Through 2029
Table 36: Global Market for Pancreatic Enzymes, by Region, Through 2029
Table 37: Global Market for Peptide Antibiotics, by Type, Through 2029
Table 38: Global Market for Peptide Antibiotics, by Region, Through 2029
Table 39: Global Market for Cyclosporine, by Region, Through 2029
Table 40: Global Market for Vancomycin, by Region, Through 2029
Table 41: Global Market for Other Peptide Antibiotics, by Region, Through 2029
Table 42: Global Market for Fusion Proteins, by Region, Through 2029
Table 43: Global Market for Protein Drugs, by Manufacturing Technology, Through 2029
Table 44: Global Market for Cell Culture, by Region, Through 2029
Table 45: Global Market for Microbial Fermentation, by Region, Through 2029
Table 46: Global Market for Natural Source Protein Manufacturing Technology, by Region, Through 2029
Table 47: Global Market for Embryonated Egg Protein Manufacturing Technology, by Region, Through 2029
Table 48: Global Market for Chemical Synthesis Protein Manufacturing Technology, by Region, Through 2029
Table 49: Global Market for Transgenics Protein Manufacturing Technology, by Region, Through 2029
Table 50: Global Market for Protein Drugs, by Region, Through 2029
Table 51: North American Market for Protein Drugs, by Type, Through 2029
Table 52: North American Market for Protein Drugs, by Manufacturing Technology, Through 2029
Table 53: North American Market for Protein Drugs, by Country, Through 2029
Table 54: Estimated Incidence of Cancer Cases in the EU, by Country, 2022
Table 55: Therapeutic MAbs Approved or Under Review in the EU, 2023 and 2024
Table 56: European Market for Protein Drugs, by Type, Through 2029
Table 57: European Market for Protein Drugs, by Manufacturing Technology, Through 2029
Table 58: European Market for Protein Drugs, by Country, Through 2029
Table 59: Asia-Pacific Market for Protein Drugs, by Type, Through 2029
Table 60: Asia-Pacific Market for Protein Drugs, by Manufacturing Technology, Through 2029
Table 61: Asia-Pacific Market for Protein Drugs, by Country, Through 2029
Table 62: RoW Market for Protein Drugs, by Type, Through 2029
Table 63: RoW Market for Protein Drugs, by Manufacturing Technology, Through 2029
Table 64: RoW Market for Protein Drugs, by Sub-Region, Through 2029
Table 65: Leading Protein Drugs, 2023
Table 66: Acquisitions in the Protein Drug Market, 2022-2024
Table 67: Product Approvals in the Protein Drug Market, 2022-2024
Table 68: Agreements and Partnerships in the Protein Drug Market, 2022-2025
Table 69: Other Strategies in the Protein Drug Market, 2022-2024
Table 70: Focus Areas in ESG Metrics
Table 71: ESG Rankings for Major Protein Drug Companies, 2024*
Table 72: ESG: Environmental Overview
Table 73: ESG: Social Factors Overview
Table 74: ESG: Governance Overview
Table 75: Abbreviations Used in this Report
Table 76: AbbVie Inc.: Company Snapshot
Table 77: AbbVie Inc.: Financial Performance, FY 2022 and 2023
Table 78: AbbVie Inc.: Product Portfolio
Table 79: AbbVie Inc.: News/Key Developments, 2023 and 2024
Table 80: Amgen Inc.: Company Snapshot
Table 81: Amgen Inc.: Financial Performance, FY 2022 and 2023
Table 82: Amgen Inc.: Product Portfolio
Table 83: Amgen Inc.: News/Key Developments, 2022-2024
Table 84: AstraZeneca: Company Snapshot
Table 85: AstraZeneca: Financial Performance, FY 2022 and 2023
Table 86: AstraZeneca: Product Portfolio
Table 87: AstraZeneca: News/Recent Developments, 2023 and 2024
Table 88: Bayer AG: Company Snapshot
Table 89: Bayer AG: Financial Performance, FY 2022 and 2023
Table 90: Bayer AG: Product Portfolio
Table 91: Bayer AG: News/Recent Developments, 2024
Table 92: Bristol-Myers Squibb Co.: Company Snapshot
Table 93: Bristol-Myers Squibb Co.: Financial Performance, FY 2022 and 2023
Table 94: Bristol-Myers Squibb Co.: Product Portfolio
Table 95: Bristol-Myers Squibb Co.: News/Key Developments, 2023
Table 96: F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 97: F. Hoffman-La Roche Ltd.: Financial Performance, FY 2022 and 2023
Table 98: F. Hoffman-La Roche Ltd.: Product Portfolio
Table 99: F. Hoffman-La Roche Ltd.: News/Key Developments, 2023 and 2024
Table 100: Johnson & Johnson Services Inc.: Company Snapshot
Table 101: Johnson & Johnson Services Inc.: Financial Performance, FY 2022 and 2023
Table 102: Johnson & Johnson Services Inc.: Product Portfolio
Table 103: Johnson & Johnson Services Inc.: News/Key Developments, 2022-2024
Table 104: Lilly: Company Snapshot
Table 105: Lilly: Financial Performance, FY 2022 and 2023
Table 106: Lilly: Product Portfolio
Table 107: Lilly: News/Key Developments, 2023 and 2024
Table 108: Merck & Co. Inc.: Company Snapshot
Table 109: Merck & Co. Inc.: Financial Performance, FY 2022 and 2023
Table 110: Merck & Co. Inc.: Product Portfolio
Table 111: Merck & Co. Inc.: News/Key Developments, 2022-2024
Table 112: Novartis AG: Company Snapshot
Table 113: Novartis AG: Financial Performance, FY 2022 and 2023
Table 114: Novartis AG: Product Portfolio
Table 115: Novartis AG: News/Key Developments, 2022-2024
Table 116: Novo Nordisk A/S: Company Snapshot
Table 117: Novo Nordisk A/S: Financial Performance, FY 2022 and 2023
Table 118: Novo Nordisk A/S: Product Portfolio
Table 119: Novo Nordisk A/S: News/Key Developments, 2023-2025
Table 120: Pfizer Inc.: Company Snapshot
Table 121: Pfizer Inc.: Financial Performance, FY 2022 and 2023
Table 122: Pfizer Inc.: Product Portfolio
Table 123: Pfizer Inc.: News/Key Developments, 2023 and 2024
Table 124: Regeneron Pharmaceuticals Inc.: Company Snapshot
Table 125: Regeneron Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
Table 126: Regeneron Pharmaceuticals Inc.: Product Portfolio
Table 127: Regeneron Pharmaceuticals Inc.: News/Key Developments, 2022 and 2023
Table 128: Sanofi: Company Snapshot
Table 129: Sanofi: Financial Performance, FY 2022 and 2023
Table 130: Sanofi: Product Portfolio
Table 131: Sanofi: News/Key Developments, 2022-2024
Table 132: Takeda Pharmaceutical Co. Ltd.: Company Snapshot
Table 133: Takeda Pharmaceutical Co. Ltd.: Financial Performance, FY 2022 and 2023
Table 134: Takeda Pharmaceutical Co. Ltd.: Product Portfolio
Table 135: Takeda Pharmaceutical Co. Ltd.: News/Key Developments, 2022-2024
List of Figures
Summary Figure: Global Market Shares of Protein Drugs, by Region, 2023
Figure 1: Desirable Characteristics of Therapeutic Proteins
Figure 2: Porter’s Five Forces Analysis: Protein Drug Market
Figure 3: Supply Chain of Protein Drugs
Figure 4: Market Dynamics Snapshot
Figure 5: Emerging Technologies in the Protein Drugs Market
Figure 6: Global Market Shares of Protein Drugs, by Type, 2023
Figure 7: Global Market Shares of MAbs, by Type, 2023
Figure 8: Global Market Shares of Peptide Hormones, by Type, 2023
Figure 9: Global Market Shares of Protein Vaccines, by Type, 2023
Figure 10: Global Market Shares of Blood Factors, by Type, 2023
Figure 11: Global Market Shares of Cytokines, by Type, 2023
Figure 12: Global Market Shares of Therapeutic Enzymes, by Type, 2023
Figure 13: Global Market Shares of Peptide Antibiotics, by Type, 2023
Figure 14: Global Market Shares of Protein Drugs, by Manufacturing Technology, 2023
Figure 15: Global Market Shares of Protein Drugs, by Region, 2023
Figure 16: North American Market Shares of Protein Drugs, by Country, 2023
Figure 17: U.S. Elderly Population (65 and Older), 2010-2050
Figure 18: European Market Shares of Protein Drugs, by Country, 2023
Figure 19: Asia-Pacific Market Shares of Protein Drugs, by Country, 2023
Figure 20: RoW Market Shares of Protein Drugs, by Sub-Region, 2023
Figure 21: Global Market Shares of MAbs, by Company, 2023
Figure 22: Global Market Shares of Peptide Hormones, by Company, 2023
Figure 23: Business Benefits of a Strong ESG Proposition
Figure 24: AbbVie Inc.: Revenue Shares, by Business Unit, FY 2023
Figure 25: AbbVie Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 26: Amgen Inc.: Revenue Shares, by Business Unit, FY 2023
Figure 27: Amgen Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 28: AstraZeneca: Revenue Shares, by Business Unit, FY 2023
Figure 29: AstraZeneca: Revenue Shares, by Region/Country, FY 2023
Figure 30: Bayer AG: Revenue Shares, by Business Unit, FY 2023
Figure 31: Bayer AG: Revenue Shares, by Region/Country, FY 2023
Figure 32: Bristol-Myers Squibb Co.: Revenue Shares, by Business Unit, FY 2023
Figure 33: Bristol-Myers Squibb Co.: Revenue Shares, by Country/Region, FY 2023
Figure 34: F. Hoffman-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2023
Figure 35: F. Hoffman-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2023
Figure 36: Johnson & Johnson Services Inc.: Revenue Shares, by Business Unit, FY 2023
Figure 37: Johnson & Johnson Services Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 38: Lilly: Revenue Shares, by Business Unit, FY 2023
Figure 39: Lilly: Revenue Shares, by Country/Region, FY 2023
Figure 40: Merck & Co. Inc.: Revenue Shares, by Business Unit, FY 2023
Figure 41: Merck & Co. Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 42: Novartis AG: Revenue Shares, by Business Unit, FY 2023
Figure 43: Novartis AG: Revenue Shares, by Country/Region, FY 2023
Figure 44: Novo Nordisk A/S: Revenue Shares, by Business Unit, FY 2023
Figure 45: Novo Nordisk A/S: Revenue Shares, by Country/Region, FY 2023
Figure 46: Pfizer Inc.: Revenue Shares, by Business Unit, FY 2023
Figure 47: Pfizer Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 48: Regeneron Pharmaceuticals Inc.: Revenue Shares, by Product Sales, FY 2023
Figure 49: Regeneron Pharmaceuticals Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 50: Sanofi: Revenue Shares, by Business Unit, FY 2023
Figure 51: Sanofi: Revenue Shares, by Country/Region, FY 2023
Figure 52: Takeda Pharmaceutical Co. Ltd.: Revenue Shares, by Business Unit, FY 2023
Figure 53: Takeda Pharmaceutical Co. Ltd.: Revenue Shares, by Region, FY 2023
